DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Optimark (Gadoversetamide) - Death - Suspected Cause - Side Effect Reports

 
 



Index of reports > Death (21)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Optimark (Gadoversetamide) death. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Optimark side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-10

Patient: male, weighing 91.0 kg (200.2 pounds)

Reactions: Pain, Joint Contracture, Muscle Fibrosis, Muscle Tightness, Myosclerosis, Fatigue, Anhedonia, Joint Range of Motion Decreased, Oedema Peripheral, Depression, Injury, Extremity Contracture, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Anxiety, Emotional Distress, Activities of Daily Living Impaired, Frustration

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: 15 ml, once
    Indication: Angiogram
    Start date: 2002-10-16
    End date: 2002-10-16

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Angiogram

Prohance
    Dosage: unk unk, once
    Indication: Angiogram
    Start date: 2002-10-16
    End date: 2002-10-16

Gadolinium IN Unspecified Drug
    Indication: Osteomyelitis

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk unk, once
    Start date: 2005-01-25
    End date: 2005-01-25

Omniscan
    Indication: Angiogram

Optimark
    Indication: Angiogram

Magnevist
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-11-15
    End date: 2002-11-15

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Indication: Diabetic Foot

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-11-05
    End date: 2002-11-05

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2005-01-14
    End date: 2005-01-14

Magnevist
    Dosage: 19 ml, once
    Start date: 2004-07-16
    End date: 2004-07-16

Other drugs received by patient: Clonidine; Fosrenol; Accupril; Renagel; Phoslo; Diatx; Vitamins NOS; Temazepam; Novolin R; Minoxidil; Insulin [insulin]; Coumadin; Procrit; Lasix



Possible Optimark side effects in 79 year old female

Reported by a physician from United States on 2012-07-20

Patient: 79 year old female, weighing 63.6 kg (140.0 pounds)

Reactions: Skin Wrinkling, Pruritus, Pain, Muscle Rigidity, Erythema, Joint Stiffness, Fatigue, Joint Range of Motion Decreased, Musculoskeletal Stiffness, Oedema, Injury, Extremity Contracture, Skin Hypertrophy, DRY Skin, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Emotional Distress, Anxiety, Arthralgia

Adverse event resulted in: death

Drug(s) suspected as cause:
Omniscan
    Dosage: dose reported as eight 20ml vials (160ml)
    Start date: 2005-09-20
    End date: 2005-09-20

Multihance
    Indication: Nuclear Magnetic Resonance Imaging Abdominal

Prohance
    Indication: Nuclear Magnetic Resonance Imaging Abdominal

Multihance
    Indication: Angiogram

Gadolinium Zeolite
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-04-25
    End date: 2001-04-25

Gadolinium Zeolite
    Start date: 2005-08-16
    End date: 2005-08-16

Omniscan
    Dosage: route reported as ^first via distal port and then via the proximal port^
    Indication: Angiogram
    Start date: 2003-12-04
    End date: 2003-12-04

Optimark
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2005-08-16
    End date: 2005-08-16

Optimark
    Indication: Angiogram

Gadolinium Zeolite
    Start date: 2001-05-03
    End date: 2001-05-03

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-04-25
    End date: 2001-04-25

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium Zeolite
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2001-03-05
    End date: 2001-03-05

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2003-05-23
    End date: 2003-05-23

Prohance
    Indication: Angiogram

Magnevist
    Indication: Angiogram
    Start date: 2001-05-03
    End date: 2001-05-03

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: dose reported as ^11^ 20ml vials
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-09-01
    End date: 2005-09-01

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Epogen; Imdur; Folic Acid; Potassium Chloride; Lovastatin; Diltiazem; Furosemide; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Renagel; Potassium Chloride; Amiodarone HCL; Hydralazine HCL; Aspirin; Niferex; Coreg; Plendil; Venofer; Zemplar



Possible Optimark side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-18

Patient: male

Reactions: Nephrogenic Systemic Fibrosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Optimark



Possible Optimark side effects in 50 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18

Patient: 50 year old male, weighing 69.8 kg (153.6 pounds)

Reactions: Muscle Contractions Involuntary, Pain, Skin Hyperpigmentation, Joint Stiffness, Skin Discolouration, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Fibrosis, General Physical Health Deterioration, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Induration, Arthralgia, Gait Disturbance, Skin Fibrosis, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: 30 ml, once
    Start date: 2000-05-05
    End date: 2000-05-05

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Start date: 2006-07-14
    End date: 2006-07-14

Magnevist
    Dosage: 48 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2000-02-05
    End date: 2000-02-05

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-12-17
    End date: 2001-12-17

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 39 ml, once
    Start date: 2006-07-26
    End date: 2006-07-26

Unspecified Gadolinium Based Contrast Agent
    Indication: Angiogram
    Start date: 2000-10-01
    End date: 2000-10-15

Magnevist
    Dosage: 40 ml, once
    Start date: 2006-08-09
    End date: 2006-08-09

Other drugs received by patient: Prednisone; Imuran; Norvasc; Calcium Carbonate; Micardis; Oxycet; Darbepoetin Alfa; Minoxidil; Percocet; Renagel; Digoxin; Clonidine; Phoslo; Lanthanum Carbonate; Ferrlecit; Florinef; Lopressor; Plaquenil; Procardia; Zemplar; Coreg; Amiodarone HCL; Aspirin; Cortisone Acetate; Renaphro; Epogen; Vancomycin; Darbepoetin Alfa; Hectorol; Fosrenol



Possible Optimark side effects in 50 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18

Patient: 50 year old male, weighing 69.8 kg (153.6 pounds)

Reactions: Muscle Contractions Involuntary, Pain, Skin Hyperpigmentation, Joint Stiffness, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Musculoskeletal Stiffness, Fibrosis, Muscular Weakness, General Physical Health Deterioration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Skin Induration, Arthralgia, Gait Disturbance, Mobility Decreased, Skin Fibrosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Unspecified Gadolinium Based Contrast Agent
    Indication: Angiogram
    Start date: 2000-10-01
    End date: 2000-10-15

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2001-12-17
    End date: 2001-12-17

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 48 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2000-02-05
    End date: 2000-02-05

Magnevist
    Dosage: 39 ml, once
    Start date: 2006-07-26
    End date: 2006-07-26

Magnevist
    Dosage: 30 ml, once
    Start date: 2000-05-05
    End date: 2000-05-05

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 40 ml, once
    Start date: 2006-08-09
    End date: 2006-08-09

Unspecified Gadolinium Based Contrast Agent
    Dosage: unk
    Start date: 2006-07-14
    End date: 2006-07-14

Other drugs received by patient: Epogen; Renagel; Procardia; Aspirin; Lopressor; Minoxidil; Ferrlecit; Zemplar; Coreg; Norvasc; Calcium Carbonate; Lanthanum Carbonate; Renaphro; Imuran; Digoxin; Florinef; Cortisone Acetate; Plaquenil; Micardis; Amiodarone HCL; Darbepoetin Alfa; Prednisone; Hectorol; Vancomycin; Darbepoetin Alfa; Phoslo; Fosrenol; Clonidine; Percocet; Oxycet



Possible Optimark side effects in 69 year old male

Reported by a physician from United States on 2012-05-08

Patient: 69 year old male, weighing 99.0 kg (217.8 pounds)

Reactions: Pruritus, Joint Contracture, Pain, Joint Stiffness, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Musculoskeletal Stiffness, Fibrosis, Extremity Contracture, Peau D'orange, Nephrogenic Systemic Fibrosis, DRY Skin, Skin Induration, Skin Tightness, Burning Sensation, Gait Disturbance, Asthenia, Cardiovascular Disorder, Skin Fibrosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: unk
    Indication: Back Pain
    Start date: 2001-03-20
    End date: 2001-03-20

Magnevist
    Dosage: 10 ml, unk
    Indication: Angioplasty
    Start date: 2002-10-02
    End date: 2002-10-02

Prohance
    Indication: Angiogram

Magnevist
    Dosage: 10 ml, unk
    Start date: 2004-12-02
    End date: 2004-12-02

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2002-02-04
    End date: 2002-02-04

Optimark
    Indication: Angiogram

Multihance
    Indication: Angiogram

Magnevist
    Dosage: unk
    Indication: Angiogram
    Start date: 2001-05-17
    End date: 2001-05-17

Omniscan
    Indication: Angiogram

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 10 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-08-25
    End date: 2006-08-25

Magnevist
    Dosage: 20 ml, unk
    Indication: Stent Placement
    Start date: 2003-05-14
    End date: 2003-05-14

Magnevist
    Dosage: 20 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2002-03-27
    End date: 2002-03-27

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 20 ml, unk
    Start date: 2002-09-09
    End date: 2002-09-09

Magnevist
    Dosage: 20 ml, unk
    Start date: 2004-10-19
    End date: 2004-10-19

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Potassium Chloride; Cardura; Aspirin; Norvasc; Demadex; Zetia; Spironolactone; Clonidine; Diltiazem; Epogen; Isosorbide Dinitrate; Quinine Sulfate; Lisinopril; Minoxidil; Nephrocaps



Possible Optimark side effects in 82 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-08

Patient: 82 year old female, weighing 69.8 kg (153.7 pounds)

Reactions: Pain, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Hyperpigmentation, Hypoaesthesia, Deformity, Muscle Tightness, Skin Tightness, Skin Plaque, Pruritus Generalised, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Musculoskeletal Stiffness, Asthenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Prohance
    Indication: Diagnostic Procedure

Magnevist
    Indication: Diagnostic Procedure

Optimark
    Indication: Diagnostic Procedure

Multihance
    Indication: Diagnostic Procedure

Omniscan
    Indication: Diagnostic Procedure

Contrast Media
    Indication: Product Used FOR Unknown Indication

Other drugs received by patient: Xalatan; Multivitamins and Iron; Colchicine; Aspirin; Lotrel; Meloxicam; Alphagan; Cosopt; Plavix; Hydrochlorothiazide; Cyproheptadine HCL; Amlodipine Besylate and Benazepril HCL; Lovenox



Possible Optimark side effects in 82 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-08

Patient: 82 year old female, weighing 69.8 kg (153.7 pounds)

Reactions: Pain, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Induration, Hypoaesthesia, Skin Hyperpigmentation, Deformity, Muscle Tightness, Skin Tightness, Skin Plaque, Pruritus Generalised, Skin Discolouration, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Asthenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Indication: Diagnostic Procedure

Multihance
    Indication: Diagnostic Procedure

Contrast Media
    Indication: Product Used FOR Unknown Indication

Optimark
    Indication: Diagnostic Procedure

Omniscan
    Indication: Diagnostic Procedure

Prohance
    Indication: Diagnostic Procedure

Other drugs received by patient: Plavix; Hydrochlorothiazide; Xalatan; Meloxicam; Colchicine; Aspirin; Lovenox; Cosopt; Alphagan; Multivitamins and Iron; Cyproheptadine HCL; Amlodipine Besylate and Benazepril HCL; Lotrel



Possible Optimark side effects in male

Reported by a consumer/non-health professional from United States on 2012-03-22

Patient: male, weighing 91.0 kg (200.2 pounds)

Reactions: Pain, Joint Contracture, Muscle Fibrosis, Muscle Tightness, Myosclerosis, Anhedonia, Fatigue, Joint Range of Motion Decreased, Oedema Peripheral, Depression, Injury, Extremity Contracture, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Anxiety, Emotional Distress, Activities of Daily Living Impaired, Frustration

Adverse event resulted in: death

Drug(s) suspected as cause:
Omniscan
    Indication: Angiogram

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Angiogram

Prohance
    Dosage: unk unk, once
    Indication: Angiogram
    Start date: 2002-10-16
    End date: 2002-10-16

Magnevist
    Dosage: 15 ml, once
    Indication: Angiogram
    Start date: 2002-10-16
    End date: 2002-10-16

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 19 ml, once
    Start date: 2004-07-16
    End date: 2004-07-16

Magnevist
    Dosage: unk unk, once
    Start date: 2005-01-25
    End date: 2005-01-25

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Angiogram

Magnevist
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-11-15
    End date: 2002-11-15

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-11-05
    End date: 2002-11-05

Other drugs received by patient: Coumadin; Temazepam; Procrit; Fosrenol; Minoxidil; Novolin R; Insulin [insulin]; Phoslo; Diatx; Vitamins NOS; Accupril; Lasix; Clonidine; Renagel



Possible Optimark side effects in female

Reported by a consumer/non-health professional from United States on 2012-03-20

Patient: female

Reactions: Pain, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Fibrosis, Deformity, Scar, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Omniscan
    Indication: Imaging Procedure

Prohance
    Indication: Imaging Procedure

Magnevist
    Indication: Imaging Procedure

Optimark
    Indication: Imaging Procedure

Multihance
    Indication: Imaging Procedure



Possible Optimark side effects in 53 year old female

Reported by a pharmacist from United States on 2012-03-19

Patient: 53 year old female, weighing 114.7 kg (252.4 pounds)

Reactions: Pruritus, Pain, Erythema, Anhedonia, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Injury, Pain in Extremity, Localised Oedema, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Tightness, Emotional Distress, Anxiety, Arthralgia, Activities of Daily Living Impaired, Skin Mass, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Xopenex; Vasotec; Demedex; Enalapril; Sensipar; Astelin; Phoslo; Vasopressin; Humulin N; Zelnorm; Ativan; Wellbutrin XL; Aspirin; Santyl; Norco; Keppra; Avandia; Allopurinol; Epogen; Aspirin; Torsemide; Neurontin; Hydrocodone Bitartrate and Acetaminophen; Synthroid; Regular Insulin; Renagel; NPH Insulin; Atrovent; Zyloprim; Mirapex; Glucotrol; Ibuprofen



Possible Optimark side effects in 69 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-02-28

Patient: 69 year old male, weighing 99.0 kg (217.8 pounds)

Reactions: Pruritus, Pain, Joint Contracture, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Musculoskeletal Stiffness, Fibrosis, Extremity Contracture, Peau D'orange, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Tightness, Burning Sensation, Gait Disturbance, Asthenia, Cardiovascular Disorder, Skin Fibrosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: unk
    Indication: Angiogram
    Start date: 2001-05-17
    End date: 2001-05-17

Magnevist
    Dosage: 20 ml, unk
    Indication: Stent Placement
    Start date: 2003-05-14
    End date: 2003-05-14

Magnevist
    Dosage: 10 ml, unk
    Start date: 2004-12-02
    End date: 2004-12-02

Omniscan
    Indication: Angiogram

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 20 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2002-03-27
    End date: 2002-03-27

Magnevist
    Dosage: 10 ml, unk
    Indication: Angioplasty
    Start date: 2002-10-02
    End date: 2002-10-02

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 20 ml, unk
    Start date: 2002-09-09
    End date: 2002-09-09

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Angiogram

Magnevist
    Dosage: 10 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-08-25
    End date: 2006-08-25

Magnevist
    Dosage: 20 ml, unk
    Start date: 2004-10-19
    End date: 2004-10-19

Magnevist
    Dosage: unk
    Indication: Back Pain
    Start date: 2001-03-20
    End date: 2001-03-20

Prohance
    Indication: Angiogram

Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2002-02-04
    End date: 2002-02-04

Optimark
    Indication: Angiogram

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Lisinopril; Cardura; Minoxidil; Demadex; Isosorbide Dinitrate



Possible Optimark side effects in female

Reported by a lawyer from United States on 2012-02-27

Patient: female, weighing 93.4 kg (205.5 pounds)

Reactions: Pain, Skin Disorder, Laceration, Muscular Weakness, Skin Induration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Erythema, Skin Tightness, Arthralgia, Swelling, Musculoskeletal Stiffness, Oedema, Skin Fibrosis, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Humulin N; Monopril; Simvastatin; Coreg; Sular; Aspirin; Darvocet; Renagel



Possible Optimark side effects in female

Reported by a physician from United States on 2012-02-27

Patient: female, weighing 82.4 kg (181.3 pounds)

Reactions: Electrocardiogram ST Segment Depression, Periorbital Cellulitis, Hypertensive Emergency, Electrocardiogram QT Shortened, Angina Unstable, Vascular Graft Thrombosis, Haematemesis, Off Label Use, Ileus, Electrocardiogram T Wave Abnormal, Arteriovenous Fistula Site Complication, Dysphagia, Nausea, Nephrogenic Systemic Fibrosis, Hyperlipidaemia, Renal Failure, Diarrhoea, QRS Axis Abnormal

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Optimark
    Dosage: 20 ml, single
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-03-24
    End date: 2005-03-24

Prohance
    Dosage: 17 ml, single
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2004-04-27
    End date: 2004-04-27

Other drugs received by patient: Norvasc; Synthroid; Zemplar; Atacand; Nephrocaps; Epogen; Renagel; Ferrlecit / 00345601 /; Insulin; Catapres / 00171101 /



Possible Optimark side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-01-12

Patient: male, weighing 76.2 kg (167.6 pounds)

Reactions: Emotional Distress, Anhedonia, Arthralgia, Skin Exfoliation, Swelling, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Extremity Contracture

Adverse event resulted in: death

Drug(s) suspected as cause:
Optimark
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Indication: Nuclear Magnetic Resonance Imaging Abdominal

Omniscan
    Dosage: 20 ml, unk
    Indication: Imaging Procedure
    Start date: 2003-11-14
    End date: 2003-11-14

Magnevist
    Dosage: unk
    Indication: Imaging Procedure
    Start date: 2005-06-17
    End date: 2005-06-17

Gadolinium IN Unspecified Drug
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Indication: Endoscopic Retrograde Cholangiopancreatography

Magnevist
    Dosage: unk
    Start date: 2005-06-28
    End date: 2005-06-28

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Arteriogram Coronary
    Start date: 1996-05-10
    End date: 1996-05-10

Gadolinium IN Unspecified Drug

Other drugs received by patient: Celebrex; Neurontin; Diovan; Lipitor; Hydrocodone Bitartrate; Glucovance; Carvedilol; Levothyroxine Sodium; Diabeta



Possible Optimark side effects in male

Reported by a consumer/non-health professional from United States on 2011-12-12

Patient: male, weighing 99.0 kg (217.8 pounds)

Reactions: Pruritus, Joint Contracture, Pain, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Musculoskeletal Stiffness, Fibrosis, Extremity Contracture, Peau D'orange, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Tightness, Burning Sensation, Gait Disturbance, Cardiovascular Disorder, Asthenia, Skin Fibrosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2002-02-04
    End date: 2002-02-04

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk
    Indication: Stent Placement
    Start date: 2003-05-14
    End date: 2003-05-14

Magnevist
    Dosage: unk
    Start date: 2004-10-19
    End date: 2004-10-19

Optimark
    Indication: Angiogram

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk
    Indication: Angioplasty
    Start date: 2002-10-02
    End date: 2002-10-02

Magnevist
    Dosage: unk
    Start date: 2004-12-02
    End date: 2004-12-02

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Angiogram

Magnevist
    Dosage: 10 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-08-25
    End date: 2006-08-25

Prohance
    Indication: Angiogram

Omniscan
    Indication: Angiogram

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: unk
    Indication: Back Pain
    Start date: 2001-03-20
    End date: 2001-03-20

Magnevist
    Dosage: unk
    Indication: Angiogram
    Start date: 2001-05-17
    End date: 2001-05-17

Magnevist
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2002-03-27
    End date: 2002-03-27

Magnevist
    Dosage: unk
    Start date: 2002-09-09
    End date: 2002-09-09



Possible Optimark side effects in 42 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-15

Patient: 42 year old male, weighing 81.0 kg (178.2 pounds)

Reactions: Skin Exfoliation, Joint Contracture, Pain, Post Inflammatory Pigmentation Change, Neuropathic Arthropathy, Stasis Dermatitis, Anhedonia, Joint Range of Motion Decreased, Skin Ulcer, Oedema, Rash Generalised, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, DRY Skin, Skin Induration, Skin Tightness, Rash Macular, Anxiety, Emotional Distress, Xerosis

Adverse event resulted in: death, disablity

Drug(s) suspected as cause:
Magnevist
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1999-08-18
    End date: 1999-08-18

Magnevist

Omniscan

Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2005-12-06
    End date: 2005-12-06

Optimark
    Dosage: 30 ml, once
    Start date: 2006-03-23
    End date: 2006-03-23

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-09-01
    End date: 2005-09-01

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain

Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-05-16
    End date: 2006-05-16

Other drugs received by patient: Levothroid; Lotrel; Epogen; Lanoxin; Phoslo; Imuran; Ascorbic Acid W / Folic Acid / Iron / Vitamin B12; Protonix; Acyclovir; Morphine; Reglan; Pravachol; Neurontin; Quinine Sulfate; Imodium; Gastromark; Avinza; Niferex; Coumadin; Lantus; Novolog; Rena-Vite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Aciphex; Nephrocaps; Cyclosporine



Possible Optimark side effects in 62 year old male

Reported by a consumer/non-health professional from United States on 2011-11-01

Patient: 62 year old male, weighing 118.0 kg (259.6 pounds)

Reactions: Pain, Cardiac Disorder, Liver Disorder, Depression, Renal Disorder, Pain in Extremity, General Physical Health Deterioration, Skin Disorder, Nephrogenic Systemic Fibrosis, Cerebrovascular Accident, Discomfort, Emotional Distress, Anxiety, Renal Failure, Arthralgia, Skin Fibrosis, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Omniscan
    Dosage: 20 ml, once
    Start date: 2005-11-17
    End date: 2005-11-17

Omniscan
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2003-09-05
    End date: 2003-09-05

Prohance
    Indication: Angiogram

Omniscan
    Dosage: 50 ml, once
    Indication: Angiogram
    Start date: 1999-12-17
    End date: 1999-12-17

Magnevist
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1996-07-12
    End date: 1996-07-12

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Dosage: 10 ml, once
    Start date: 2008-03-26
    End date: 2008-03-26

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Angiogram

Magnevist
    Dosage: 10 ml, once
    Indication: Angiogram
    Start date: 2006-08-10
    End date: 2006-08-10

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Angiogram

Other drugs received by patient: Aspirin [acetylsalicylic Acid,calcium Carbonate,citric Acid]; Hydrochlorothiazide; Metoprolol Tartrate; Enalapril Maleate; Plavix; Vitamin TAB; Lantus; Humalog; Crestor; Metformin HCL; Venlafaxine; Alprazolam



Possible Optimark side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-27

Patient: male, weighing 76.2 kg (167.6 pounds)

Reactions: Emotional Distress, Anhedonia, Arthralgia, Skin Exfoliation, Swelling, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Extremity Contracture

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: unk
    Start date: 2005-06-28
    End date: 2005-06-28

Gadolinium IN Unspecified Drug
    Indication: Endoscopic Retrograde Cholangiopancreatography

Omniscan
    Dosage: 20 ml, unk
    Indication: Imaging Procedure
    Start date: 2003-11-14
    End date: 2003-11-14

Gadolinium IN Unspecified Drug

Gadolinium IN Unspecified Drug
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug

Magnevist
    Dosage: unk
    Indication: Imaging Procedure
    Start date: 2005-06-17
    End date: 2005-06-17

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Arteriogram Coronary
    Start date: 1996-05-10
    End date: 1996-05-10

Gadolinium IN Unspecified Drug
    Indication: Nuclear Magnetic Resonance Imaging Abdominal

Other drugs received by patient: Glucovance; Diovan; Diabeta; Lipitor; Levothyroxine Sodium; Hydrocodone Bitartrate; Carvedilol; Celebrex; Neurontin



Possible Optimark side effects in 60 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-24

Patient: 60 year old male, weighing 118.0 kg (259.6 pounds)

Reactions: Pain, Cardiac Disorder, Liver Disorder, Depression, Renal Disorder, Pain in Extremity, Skin Disorder, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Cerebrovascular Accident, Discomfort, Anxiety, Emotional Distress, Renal Failure, Arthralgia, Skin Fibrosis, Mobility Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Magnevist
    Dosage: unk unk, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1996-07-12
    End date: 1996-07-12

Prohance
    Indication: Angiogram

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist

Omniscan
    Dosage: 20 ml, once
    Start date: 2005-11-17
    End date: 2005-11-17

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: 50 ml, once
    Indication: Angiogram
    Start date: 1999-12-17
    End date: 1999-12-17

Omniscan
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2003-09-05
    End date: 2003-09-05

Optimark
    Indication: Angiogram

Multihance
    Indication: Angiogram

Magnevist
    Dosage: 10 ml, unk
    Indication: Angiogram
    Start date: 2006-08-10
    End date: 2006-08-10

Magnevist
    Dosage: 10 ml, once
    Start date: 2008-03-26
    End date: 2008-03-26

Other drugs received by patient: Lantus; Humalog; Hydrochlorothiazide; Venlafaxine; Vitamin TAB; Plavix; Aspirin [acetylsalicylic Acid,calcium Carbonate,citric Acid]; Crestor; Enalapril Maleate; Alprazolam; Metoprolol Tartrate; Metformin HCL



Possible Optimark side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-06

Patient: male, weighing 76.2 kg (167.6 pounds)

Reactions: Skin Exfoliation, Pain, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Emotional Distress, Anhedonia, Arthralgia, Swelling, Extremity Contracture

Adverse event resulted in: death

Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Arteriogram Coronary
    Start date: 1996-05-10
    End date: 1996-05-10

Gadolinium IN Unspecified Drug

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2005-06-17
    End date: 2005-06-17

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Imaging Procedure

Omniscan
    Dosage: 20 ml, unk
    Indication: Imaging Procedure
    Start date: 2003-11-14
    End date: 2003-11-14

Optimark
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Indication: Endoscopic Retrograde Cholangiopancreatography

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-06-23
    End date: 2005-06-23

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2005-06-28
    End date: 2005-06-28

Other drugs received by patient: Diovan; Celebrex; Glucovance; Lipitor; Carvedilol; Diabeta; Levothyroxine Sodium; Neurontin; Hydrocodone Bitartrate

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012